STOCK TITAN
  1. Home
  2. News
  3. BBIO

BridgeBio Pharma Inc - BBIO STOCK NEWS

Welcome to our dedicated news page for BridgeBio Pharma (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on BridgeBio Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BridgeBio Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BridgeBio Pharma's position in the market.

News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
BridgeBio Pharma, Inc. announced equity grants to new employees totaling 93,088 shares of common stock. The grants vest over time, subject to continued employment. The awards were made under the Amended and Restated 2019 Inducement Equity Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
none
-
News
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Rhea-AI Summary
BridgeBio Pharma, Inc. (BBIO) presents positive results from a CMR imaging substudy of ATTRibute-CM Phase 3 trial of acoramidis in ATTR-CM, showing potential cardiac structural and functional improvement with acoramidis treatment. The data support near-complete TTR stabilization with acoramidis leading to cardiac remodeling and functional recovery. Acoramidis was well-tolerated with no safety concerns. BridgeBio's NDA for acoramidis has been accepted by the FDA and MAA by the EMA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
BridgeBio Pharma, Inc. approved equity grants for 16 new employees totaling 71,146 shares of common stock. The grants vest over time and were made under the Amended and Restated 2019 Inducement Equity Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
News
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
Rhea-AI Summary
BridgeBio Pharma, Inc. announces a public offering of 8,620,690 shares of common stock at $29.00 per share, expecting gross proceeds of approximately $250.0 million. The offering includes an option for underwriters to purchase additional shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
offering
-
News
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
BridgeBio Pharma, Inc. announces a $250 million public offering of common stock, with an option for additional $37.5 million, managed by J.P. Morgan, Cantor Fitzgerald & Co., and Mizuho. The offering is subject to market conditions and regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
offering
-
News
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
Rhea-AI Summary
BridgeBio grants Bayer exclusive license to commercialize acoramidis for ATTR-CM in Europe, receiving up to $310 million USD, royalties in low-thirties percent, and potential sales milestones. Positive Phase 3 trial results led to FDA and EMA acceptance, with Bayer's expertise enhancing commercialization efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.19%
Tags
none
News
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Rhea-AI Summary
BridgeBio Pharma, Inc. submits NDA for acoramidis to FDA for ATTR-CM treatment, presents positive Phase 3 trial results, secures funding, and reports financial results for Q4 and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
earnings
-
News
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
Rhea-AI Summary
BridgeBio Pharma, Inc. and Kyowa Kirin Co., Ltd announced a partnership for the development and commercialization of infigratinib for achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan. BridgeBio will receive an upfront payment of USD 100 million and royalties on sales of infigratinib in Japan. Infigratinib is an oral small molecule designed to inhibit FGFR3 and target FGFR3-driven skeletal dysplasias, including achondroplasia and hypochondroplasia. The partnership aims to accelerate the development of infigratinib to provide treatment options for children with achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
partnership
-
News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
BridgeBio Pharma, Inc. granted 123,838 shares of common stock to 35 new employees as part of their compensation package. The shares will vest over time, subject to continued employment. The awards were made under the company's 2019 Inducement Equity Plan, adopted in November 2019 and subsequently amended in February and December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
News
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Rhea-AI Summary
BridgeBio Pharma, Inc. announces that the U.S. FDA has accepted the New Drug Application (NDA) for acoramidis, a drug for the treatment of ATTR-CM, with a PDUFA action date of November 29, 2024. The FDA is not planning to hold an advisory committee meeting. The European Medicines Agency has also accepted the Marketing Authorization Application, with additional global regulatory submissions planned. ATTRibute-CM study results showed positive outcomes, including an 81% absolute survival rate, low cardiovascular-related hospitalization frequency, and rapid clinical benefit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
Stock BBIO logo
BridgeBio Pharma Inc

Nasdaq:BBIO

BBIO Rankings

#1242 Ranked by Market Cap
#87 Ranked by Stock Gains
N/A Ranked by Dividends

BBIO Stock Data

4.66B
113.02M
5.37%
92.14%
7.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Palo Alto

About BBIO

we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.